Speakers

Expand/Collapse

Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

6:30 pm | Chair’s Closing Remarks

Alison Crawford
Associate Director of Immuno-oncology
Regeneron

Pre-Conference Workshop

June 29, 2021

12:05 pm | Speaker Q&A

11:15 am | Examining Toxicity Mitigation Strategies To CD3 Bispecifics In Humanized Mouse Models

Laurent Gauthier
Senior Director
Innate Pharma

Day One

Wednesday, June 30, 2021

11:00 am | Multi-functional Natural Killer Cell Engagers

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

Imaj Ajjawi
VP of Business Development
Absci

Marta Germani
Research Analyst
Beacon Targeted Therapies

Day One

Wednesday, June 30, 2021

8:05 am | Landscape Review of CD3 Bispecifics

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

Eric Vivier
Chief Scientific Officer
Innate Pharma

Mohamed Elmeliegy
Associate Director Clinical Pharmacology
Pfizer

Day Two

Thursday, July 1, 2021

8:05 am | Chair’s Opening Remarks

Pre-Conference Workshop

June 29, 2021

12:45 pm | Round Table: Developing A Dosing Strategy For Clinical Trial Investigations

Matthew Weinstock
Chief Technology Officer
Absci

Day One

Wednesday, June 30, 2021

9:20 am | Absci's Revolutionary Approach to Discovering Novel T-Cell Engagers in Scalable Manufacturing Cell Lines

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

Erin Meermeier
Senior Research Fellow
Mayo Clinic

Pre-Conference Workshop

June 29, 2021

1:45 pm | Developing Combination Approaches Using Immunocompetent Vk*MYChCRBN Genetically Engineered Humanized Model Of Multiple Myeloma

Maya Kotturi
Director of Preclinical Biomarkers
IGM Biosciences

Pre-Conference Workshop

June 29, 2021

2:10 pm | Developing A Preclinical Biomarker Strategy For Assessing Efficacy and Safety of Bispecific T Cell Engagers

Peter Pavlik
Director of Molecular Biology and Antibody Engineering
Aptevo Therapeutics

Day One

Wednesday, June 30, 2021

10:35 am | Live Q&A - Ask our Speakers Your Burning Questions

9:45 am | Engineering of APVO442, a bispecific molecule with high affinity tumor targeting and low affinity binding to CD3 to potentially improve efficacy in solid tumors

Oren Bogin
Chief Executive Officer
Immunorizon

Day Two

Thursday, July 1, 2021

5:00 pm | Chair’s Closing Remarks

Catherine McMahan
Senior Director of Pharmacology & Cell Sciences
Aptevo Therapeutics

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Hilario Ramos
Senior Director of Immuno-Biology
Aptevo Therapeutics

Day One

Wednesday, June 30, 2021

4:00 pm | APVO603: A distinct dual agonistic bispecific approach to facilitate anti-tumor activity and overcome limitations of monoclonal OX-40 and 4-1BB targeting

4:25 pm | Live Q&A - Ask our Speakers Your Burning Questions

Chris Hughes
CSO
Aracari Biosciences

Day One

Wednesday, June 30, 2021

12:45 pm | Live Q&A - Ask our Speakers Your Burning Questions

12:30 pm | The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery

James Keck
Senior Director, Innovation and Product Development
The Jackson Laboratory

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

11:00 am | De-risking Therapeutic Antibody Preclinical Drug Development: Simultaneous Assessment of Efficacy and Toxicity in Humanized Mice

Suhasini Iyer
Chief Development Officer
TeneoBio

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Pieter Fokko van Loo
Senior Director, Oncology - Immunology
Merus

Day One

Wednesday, June 30, 2021

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

11:25 am | Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers

Christian Klein
Department Head Cancer Immunotherapy Discovery
Roche

Day One

Wednesday, June 30, 2021

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

8:30 am | Novel Approaches for T-Cell Engagement

Bryan Irving
Chief Scientific Officer
Amunix Pharmaceuticals

Andrew Pierce
VP Translational Biology
Crescendo Biologics

Day One

Wednesday, June 30, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:30 pm | CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism

Nelly Kuklin
VP Immunology
Compass Therapeutics

Day One

Wednesday, June 30, 2021

12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

11:50 am | Bispecific Anti-PD-1/PD-L1 Antibody CTX-8371 Promotes Immunological Synapse Formation & PD-1 Shedding With Superior Anti-Tumor Activity & Favorable Tolerability

Yiping Rong
Head of Discovery Biology
Harbour Biomed

Day One

Wednesday, June 30, 2021

4:25 pm | Live Q&A - Ask our Speakers Your Burning Questions

3:35 pm | HBICETM-Based B7H4x4-1BB Bispecific Provides Tumor Specific 2nd Costimulatory Signal & Anti-Tumor Immune Response

Nicholas Huntington
Co-Founder & Chief Scientific Officer
oNKo-innate

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:05 pm | Tuning the NK Cell Response to Soluble Factors in the Tumor Microenvironment

Tatiana Novobrantseva
Co-Founder & Chief Scientific Officer
Verseau Therapeutics

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:30 pm | Macrophage Repolarization as a Key Strategy in Changing Tumor Microenvironment

Saileta Prabhu
VP/Global Head, Clinical Biomarker Innovation & Development
Takeda

Day Two

Thursday, July 1, 2021

4:50 pm | Live Q&A - Ask our Speakers Your Burning Questions

4:00 pm | ROI on Clinical Biomarkers, CDx and Precision Medicine

David DiLillo
Associate Director
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

10:35 am | Live Q&A - Ask our Speakers Your Burning Questions

10:10 am | Benchmarking T-cell -Redirecting Therapies for Cancer: Comparing Bispecifics & CAR T Cells

Patricia Giblin
VP of Biology
Revitope Oncology

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

10:50 am | Live Q&A - Ask our Speakers Your Burning Questions

10:00 am | Improving the Therapeutic Index with Guided Antibody Tumor Engagers (GATETM)

Lily Pao
Head of Immuno- Oncology Cluster, Immuno-Oncology Therapeutic Area
Sanofi

Day Two

Thursday, July 1, 2021

8:15 am | Multispecific Immune Cell Engagers for Cancer Immunotherapy

9:30 am | Live Q&A - Ask our Speakers Your Burning Questions

Floris van Delft
Chief Scientific Officer
Synaffix

Day Two

Thursday, July 1, 2021

9:30 am | Live Q&A - Ask our Speakers Your Burning Questions

9:05 am | Generation of Bispecific & Trispecific T-Cell & NK Cell- Engagers From Any IgG Without Prior Reengineering

Fernanda Arnaldez
Executive Director - Medical & Global Clinical Development
MacroGenics

Wim van Schooten
Chief Scientific Officer
TeneoBio

Day Two

Thursday, July 1, 2021

1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

1:30 pm | Safety & Efficacy of T-Cell Engagers with Low Agonist Activity in Oncology & Infectious Diseases

Chad May
SVP Research & Development
Maverick Therapeutics

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Brian Rabinovich
Director
EMD Serono

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Lukas Roth
Senior Scientist, Protein Engineering and Antibody Technologies
Merck KGaA

Day One

Wednesday, June 30, 2021

6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

5:00 pm | Affinity Maturation of B7-H6 Translates Into Enhanced NK Cell-Mediated Tumor Cell Lysis & Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement

Michael Hedvat
Associate Director
Xencor

Day One

Wednesday, June 30, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:55 pm | Tumor-Targeted CD28 Costimulatory Bispecific Antibodies Enhance T-Cell Activation in Solid Tumors

Joachim Koch
Head of Translational Research & Innovation
Affimed GmbH

Day One

Wednesday, June 30, 2021

6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

5:50 pm | Combination Therapies with Innate Cell Engagers to Fight for Patients in Need

Julie Bailis
Director of Research
Amgen

Day One

Wednesday, June 30, 2021

9:35 am | Live Q&A - Ask our Speakers Your Burning Questions

8:55 am | Targeting Prostate Cancer with T-Cell Engager Immune Therapies

Day Two

Thursday, July 1, 2021

11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Janet Peper
Senior Scientist, Translational Science
Pieris Pharmaceuticals

Day One

Wednesday, June 30, 2021

2:05 pm | Tumor-localized 4-1BB Agonism in Immuno-Oncology

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

Divya Mathur
Director of Immuno-oncology
Regeneron Pharmaceuticals

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

8:00 am | Opening address from chair

Nuzhat Pathan
Senior Director, Translational and Immuno-Oncology
Pfizer

Day Two

Thursday, July 1, 2021

4:50 pm | Live Q&A - Ask our Speakers Your Burning Questions

4:25 pm | Biomarker strategies for optimal Immuno-Oncology combinations

Danielle Dettling
Senior Director, Pre- Clinical Pharmacology
Maverick Therapeutics

Day Two

Thursday, July 1, 2021

10:25 am | Utilizing its conditionally activated COBRA platform in the solid tumor space to demonstrate an improved therapeutic window over conventional T-cell engagers

10:50 am | Live Q&A - Ask our Speakers Your Burning Questions

Gosia Nocula-Lugowska
Principal Scientist
Pfizer

Day Two

Thursday, July 1, 2021

8:40 am | Optimizing T-cell Bispecifics in the Treatment of Solid Tumors

9:30 am | Live Q&A - Ask our Speakers Your Burning Questions

Pre-Conference Workshop

June 29, 2021

12:05 pm | Speaker Q&A

11:40 am | Review Types and Sources of Toxicity for T-Cell Retargeting Bi and Multi-Specific Antibodies

Rick Austin
Vice President, Research
Harpoon Therapeutics

Day Two

Thursday, July 1, 2021

3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions

2:55 pm | Presentation Title To Be Announced

Hans van der Vliet
CSO
Lava Therapeutics

Day One

Wednesday, June 30, 2021

6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions

5:25 pm | Bispecific Antibodies to Engage Vγ9Vδ2-T Cells for Cancer Immunotherapy

Bruce Keyt
Chief Scientific Officer
IGM Biosciences

Day One

Wednesday, June 30, 2021

1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor

Day Two

Thursday, July 1, 2021

1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions

1:05 pm | Improving the Therapeutic Window of T-Cell Engagers